Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Novo fails trial, linking obesity asset to psychiatric effects
Months after sharing obesity data that left investors underwhelmed, Novo has reported the failure of a midphase diabetic kidney disease trial.
Nick Paul Taylor
Feb 5, 2025 7:39am
Cargo offloads CAR-T, 50% of staff over efficacy, side effects
Jan 30, 2025 8:05am
Inhibikase hits pause on Parkinson's program over efficacy
Jan 30, 2025 4:30am
BioAge axes obesity asset over liver toxicity
Jan 28, 2025 10:11am
Allakos axes program, lays off 75% of staff after phase 1 flop
Jan 27, 2025 8:46am
Neumora's dig into phase 3 depression data disappoints analysts
Jan 15, 2025 9:35am